← Leaderboards
Paul Sax
Brigham And Women'S Hospital
$75,148
Attributed
$75,148
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $59.5K · FY2006–08$100K$75K$50K$25K$0
'06
'07
'08
Funding mix
By agency
NIH$75,148 · 11
By mechanism
M01$75,148 · 11
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Holly Elizabeth Rawizza$3,045,812
- Daniel R Kuritzkes$313,891,104
- Kenneth H Mayer$64,411,257
- Peter R Chai$5,626,740
- Jonathan Li$17,759,976
Others in their field
Top investigators on “Grant”
- David R. Weir · University Of Michigan At Ann Arbor$373,949,788
- David Heimbrook · Leidos Biomedical Research, Inc.$341,196,902
- Eric S Lander · Whitehead Institute For Biomedical Res$323,181,457
- Jeffrey P Krischer · University Of South Florida$258,583,867
- Lawrence Corey · Fred Hutchinson Cancer Center$253,286,867
- Barton F Haynes · Duke University$243,251,908
Research focus
GrantFundingUnited States National Institutes Of HealthSourceResourcesResearch PersonnelComputer Retrieval Of Information On Scientific Projects DatabasePurposeInstitutionHiv InfectionsLearningAdultAnti-Hiv AgentsGaggingGenes, EnvFightingHiv-1EmtricitabineEfavirenzLabelDrug CombinationsLinkLopinavir/RitonavirMedicine
Grant awards (11)
A5202: A PHASE III TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR$4,810
M01 · FY2008 · RR · contact PI
ALLRT: ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS$3,331
M01 · FY2008 · RR · contact PI
HIV-1 DNA VRC-HIV 009-00 VP (GAG-POL-NEF_MULTICLADE ENV) IN HIV-1$2,220
M01 · FY2008 · RR · contact PI
THE SETPOINT STUDY: DOES EARLY THERAPY ALTER THE VIROLOGIC SETPOINT?$1,110
M01 · FY2008 · RR · contact PI
A PHASE IV STUDY OF ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS$741
M01 · FY2008 · RR · contact PI
A5202: A PHASE III TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR$23,436
M01 · FY2007 · RR · contact PI
ALLRT: ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS$16,226
M01 · FY2007 · RR · contact PI
HIV-1 DNA VRC-HIV 009-00 VP (GAG-POL-NEF_MULTICLADE ENV) IN HIV-1$10,818
M01 · FY2007 · RR · contact PI
THE SETPOINT STUDY: DOES EARLY THERAPY ALTER THE VIROLOGIC SETPOINT?$5,409
M01 · FY2007 · RR · contact PI
A PHASE IV STUDY OF ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS$3,608
M01 · FY2007 · RR · contact PI
HIV-1 DNA VRC-HIV 009-00 VP (GAG-POL-NEF-MULTICLADE ENV) IN HIV-1$3,439
M01 · FY2006 · RR · contact PI